J M Martinez1, A Anene2, T G K Bentley2, M J Cangelosi3, L M Meckley4, J D Ortendahl2, A J Montero5. 1. University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, USA. michael.cangelosi@bsci.com. 2. Partnership for Health Analytic Research, LLC, Beverly Hills, CA, USA. 3. Boston Scientific Corporation, Marlborough, MA, USA. 4. Shire PLC, Dublin, Ireland. 5. Cleveland Clinic Foundation, Taussig Cancer Institute, Cleveland, OH, USA.
Abstract
BACKGROUND: ASGE and ESGE guidelines recommend endoscopic metal stent placement for pancreatic carcinoma patients with biliary obstruction, and whose estimated life expectancy is greater than 6 months. Because median overall survival (OS) of metastatic pancreatic adenocarcinoma until recently has been less than 6 months, plastic biliary stents were preferentially placed rather than metal due to the greater upfront cost of the latter. Recent advances in the treatment of metastatic pancreatic cancer have extended median OS beyond the 6-month range. Given this improvement in OS, we performed a cost-effectiveness analysis of initial metal biliary versus plastic stent placement in metastatic pancreatic cancer patients with biliary obstruction. METHODS: A Markov model was developed to predict lifetime costs, quality-adjusted life years (QALYs), and cost effectiveness of metal compared with plastic stents. Adult patients entered the model with locally advanced cancer and underwent endoscopic retrograde cholangiopancreatography (ERCP) with placement of metal or plastic stents. A targeted literature search was conducted to identify published sources, which were used to estimate clinical, cost, utility, and event rate inputs to the model. Results were estimated from the third-party payer perspective in 2012 US dollars per QALY. One-way and probabilistic sensitivity analyses were conducted to assess the impact on model outcomes resulting from uncertainty among inputs. RESULTS: Our analysis found that initial placement of metal stents was more cost effective than plastic biliary stents with lower overall costs due to lower restenting rates while at the same time associated with a better quality of life. Based on model projections, placement of metal stents could save approximately $1450 per patient over a lifetime, while simultaneously improving quality of life. These findings were robust in sensitivity analyses. CONCLUSIONS: Placement of metal biliary stents at initial onset of obstructive jaundice in adult patients with metastatic pancreatic carcinoma with an expected OS greater than 6 months was found to be a more cost-effective strategy than plastic stents. These results reinforce guidelines' suggestions for metal stent placement.
BACKGROUND: ASGE and ESGE guidelines recommend endoscopic metal stent placement for pancreatic carcinomapatients with biliary obstruction, and whose estimated life expectancy is greater than 6 months. Because median overall survival (OS) of metastatic pancreatic adenocarcinoma until recently has been less than 6 months, plastic biliary stents were preferentially placed rather than metal due to the greater upfront cost of the latter. Recent advances in the treatment of metastatic pancreatic cancer have extended median OS beyond the 6-month range. Given this improvement in OS, we performed a cost-effectiveness analysis of initial metal biliary versus plastic stent placement in metastatic pancreatic cancerpatients with biliary obstruction. METHODS: A Markov model was developed to predict lifetime costs, quality-adjusted life years (QALYs), and cost effectiveness of metal compared with plastic stents. Adult patients entered the model with locally advanced cancer and underwent endoscopic retrograde cholangiopancreatography (ERCP) with placement of metal or plastic stents. A targeted literature search was conducted to identify published sources, which were used to estimate clinical, cost, utility, and event rate inputs to the model. Results were estimated from the third-party payer perspective in 2012 US dollars per QALY. One-way and probabilistic sensitivity analyses were conducted to assess the impact on model outcomes resulting from uncertainty among inputs. RESULTS: Our analysis found that initial placement of metal stents was more cost effective than plastic biliary stents with lower overall costs due to lower restenting rates while at the same time associated with a better quality of life. Based on model projections, placement of metal stents could save approximately $1450 per patient over a lifetime, while simultaneously improving quality of life. These findings were robust in sensitivity analyses. CONCLUSIONS: Placement of metal biliary stents at initial onset of obstructive jaundice in adult patients with metastatic pancreatic carcinoma with an expected OS greater than 6 months was found to be a more cost-effective strategy than plastic stents. These results reinforce guidelines' suggestions for metal stent placement.
Entities:
Keywords:
Biliary stents; Endoscopic retrograde cholangiopancreatography; Obstructive jaundice; Pancreatic cancer
Authors: Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux Journal: N Engl J Med Date: 2011-05-12 Impact factor: 91.245
Authors: Cristina Gómez-Oliva; Carlos Guarner-Argente; Mar Concepción; Francisco Javier Jiménez; Sarbelio Rodríguez; Ferran Gonzalez-Huix; Fernando Mugica; José Luis Cabriada; Claudio Rodríguez; Carlos Guarner Aguilar Journal: Surg Endosc Date: 2011-08-20 Impact factor: 4.584
Authors: Mihir Bakhru; Henry C Ho; Vishal Gohil; Andrew Y Wang; Kristi Ellen; Bryan G Sauer; Vanessa M Shami; Michel Kahaleh Journal: J Gastroenterol Hepatol Date: 2011-06 Impact factor: 4.029
Authors: Mouen A Khashab; Katherine Kim; Susan Hutfless; Anne Marie Lennon; Anthony N Kalloo; Vikesh K Singh Journal: Dig Dis Sci Date: 2012-05-10 Impact factor: 3.199
Authors: Steffi J Rombouts; Marieke S Walma; Jantien A Vogel; Lennart B van Rijssen; Johanna W Wilmink; Nadia Haj Mohammad; Hjalmar C van Santvoort; I Quintus Molenaar; Marc G Besselink Journal: Ann Surg Oncol Date: 2016-07-01 Impact factor: 5.344